Patent
While the method to develop antibodies using EB virus has been known for a long time, successful materialization of the technique is very rare. We devised our unique technique to stably develop target antibodies by accumulating the know-how of preparing high-titer EB virus, culture and cloning of EB-virus-infected lymphocytes, and sorting lymphocytes producing antibodies of particular interest. Our antibodies can be a subject for substance patent. To this date, 11 patent applications have been made.
